← Back to Search

Deep Brain Stimulation

Deep Brain Stimulation for Parkinson's Disease

N/A
Waitlist Available
Led By Drew S Kern, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with Parkinson's Disease
Patients with no current deep brain stimulating electrodes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week
Awards & highlights

Study Summary

This trial is testing whether electrical stimulation of the rZI, in addition to the STN, can provide relief from Parkinson's disease symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
People with Parkinson's disease are not eligible.
Select...
You do not have any deep brain stimulating electrodes in place.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Motor testing
Secondary outcome measures
Anxiety
Cognition
Depression
+4 more

Side effects data

From 2018 Phase 2 trial • 53 Patients • NCT01221948
23%
Fall
15%
Depression
8%
Hand fracture
8%
Restless legs syndrome
8%
Apathy
5%
Back pain
5%
Head injury
5%
Speech disorder
5%
Skeletal injury
5%
Tremor
5%
Gait disturbance
5%
Dystonia
5%
Paraesthesia
5%
Influenza
5%
Urinary tract infection
5%
Dyspepsia
3%
Akinesia
3%
Diabetes mellitus
3%
Intervertebral disc protrusion
3%
Device migration
3%
Postoperative wound infection
3%
Parkinson's disease
3%
Productive cough
3%
Fluid retention
3%
Skin laceration
3%
Respiratory depression
3%
Joint sprain
3%
Syncope
3%
Ingrowing nail
3%
Rib fracture
3%
Drug withdrawal syndrome
3%
Alcohol poisoning
3%
Contusion
3%
Cerebral microangiopathy
3%
Dysarthria
3%
Hypoaesthesia
3%
Memory impairment
3%
Movement disorder
3%
Monarthritis
3%
Neck pain
3%
Osteoarthritis
3%
Pain in extremity
3%
Spinal osteoarthritis
3%
Adverse drug reaction
3%
Cyst
3%
Implant site haematoma
3%
Oedema peripheral
3%
Pyrexia
3%
Pleural effusion
3%
Nerve root lesion
3%
Anxiety
3%
Cough
3%
Fibula fracture
3%
Thermal burn
3%
Sciatica
3%
Anger
3%
Bursitis
3%
Cystitis
3%
Helicobacter gastritis
3%
Implant site infection
3%
Localised infection
3%
Pneumonia
3%
Staphylococcal infection
3%
Confusional state
3%
Depressed mood
3%
Hallucination, auditory
3%
Impulse-control disorder
3%
Insomnia
3%
Panic attack
3%
Rapid eye movements sleep abnormal
3%
Bronchitis
3%
Ear infection
3%
Incision site infection
3%
Arthralgia
3%
Axillary pain
3%
Folate deficiency
3%
Hypertension
3%
Hypotension
3%
Thrombophlebitis
3%
Diplopia
3%
Macular degeneration
3%
Laboratory test abnormal
3%
Weight increased
3%
Pericardial effusion
3%
Seborrhoeic keratosis
3%
Urinary incontinence
100%
80%
60%
40%
20%
0%
Study treatment Arm
Deep Brain Stimulation

Trial Design

2Treatment groups
Experimental Treatment
Group I: 2Experimental Treatment1 Intervention
rZI + STN stimulation
Group II: 1Experimental Treatment1 Intervention
STN Monopolar Stimulation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deep Brain Stimulation
2011
Completed Phase 2
~700

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,726 Previous Clinical Trials
2,141,676 Total Patients Enrolled
Drew S Kern, MDPrincipal InvestigatorUniversity of Colorado, Denver

Media Library

Deep Brain Stimulation (Deep Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT03212885 — N/A
Parkinson's Disease Research Study Groups: 2, 1
Parkinson's Disease Clinical Trial 2023: Deep Brain Stimulation Highlights & Side Effects. Trial Name: NCT03212885 — N/A
Deep Brain Stimulation (Deep Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03212885 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Mar 2025